A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

NCT ID: NCT04420884

Last Updated: 2025-06-13

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 248 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-07-22
• Study Completion Date: 2026-03-31

Brief Summary

The main aim of this study is to check if people with advanced solid tumors have side effects from dazostinag, and to check how much dazostinag they can receive without getting significant side effects from it when given alone and in combination with pembrolizumab. The study will be conducted in two phases including a dose escalation phase and a dose expansion phase. In the dose escalation phase, escalating doses of dazostinag are being tested alone and in combination with pembrolizumab to treat participants who have advanced or metastatic solid tumors. In the dose expansion phase, dazostinag will be studied with pembrolizumab with or without chemotherapy in participants with untreated metastatic or recurrent, unresectable squamous cell carcinoma of head and neck (SCCHN) and in combination with pembrolizumab in third-line or later recurrent locally advanced or metastatic microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) and third-line recurrent locally advanced or metastatic microsatellite stable/mismatch repair proficient (MSS/pMMR) colorectal cancer (CRC).

Detailed Description

The drug being tested in this study is called dazostinag. Dazostinag is being tested to treat people who have advanced or metastatic solid tumors.

The study will enroll approximately 374 participants. Part 1 consists of an initial Safety Lead-in to Dose Escalation Phase; Part 2 and Part 3 compose the Expansion Phase in 2 specific indications namely, previously untreated metastatic or recurrent, unresectable SCCHN (Part 2) and third-line or later recurrent locally advanced or metastatic MSI-H/dMMR and third-line recurrent locally advanced or metastatic MSS/pMMR CRC (Part 3). Participants will be assigned to the following treatment groups in the respective Phases of the study:

• Part 1 (Dose Escalation Phase): Safety Lead-in + Dazostinag single agent (SA) [Part 1A] Dazostinag 0.1 milligram (mg) in the Safety Lead-in followed by Dazostinag as escalating doses (0.2 mg and above) in Part 1A
• Part 1B (Combination Dose Escalation Phase): Dazostinag as escalating doses (0.2 mg and above) + Pembrolizumab
• Japan Safety Lead-in: Dazostinag SA 5.0 mg in the Safety Lead-in± Pembrolizumab in Arms A and B. Additional dose levels of Dazostinag (such as 14.0 mg) in combination with pembrolizumab may be explored during the Japan safety lead-in considering recommended dose for expansion (RDE1) as 5.0 mg and dose optimization.

Once a safe dose is recommended from Part 1, participants of select advanced or metastatic solid tumors will receive dazostinag in below defined cohorts in the expansion phase:

• Part 2A (SCCHN Combined Positive Score [CPS] ≥ 1 Dose Expansion Phase): Dazostinag + Pembrolizumab*
• Part 2B (SCCHN Dose Expansion Phase): Dazostinag + Pembrolizumab + Chemotherapy
• Part 3A (Expansion Phase in CRC): Dazostinag + Pembrolizumab in MSI-H/dMMR CRC
• Part 3B (Expansion Phase in CRC): Dazostinag + Pembrolizumab in MSS/pMMR CRC

This multi-center trial will be conducted worldwide. The overall time to participate in this study is 68 months. Participants will make multiple visits to the clinic, including 30 days after last dose of study drug for a follow-up assessment. Participants in Parts 2 and 3 will be followed for survival for up to 12 months after the last dose of study drug.

Conditions

Solid Neoplasms

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Part 1 (Monotherapy Dose Escalation Phase): Dazostinag Safety Lead-in + Dazostinag SA [Part 1A]

Safety Lead-in: Dazostinag 0.1 mg, infusion, intravenously (IV), once weekly, on Days 1, 8 and 15 in 21-day treatment cycles.

Dazostinag SA Dose Escalation (Part 1A): Dazostinag single agent (SA), infusion, IV, once weekly on Days 1, 8 and 15 in each 21-day treatment cycles with escalating doses (0.2 mg and above). The dosing will be initiated in the Dazostinag SA Dose Escalation Phase based on the available safety and tolerability data from the Safety Lead-in.

Group Type: EXPERIMENTAL

Dazostinag

Intervention Type: DRUG

Dazostinag intravenous infusion.

Part 1B (Combination Dose Escalation Phase): Dazostinag + Pembrolizumab

Dazostinag escalating doses (0.2 mg and above) in combination with pembrolizumab 200 mg, infusion, IV, once weekly on Days 1, 8 and 15 in each 21-day treatment cycle. Pembrolizumab 200 mg will be administered 1 hour prior to Dazostinag once every 3 weeks (Q3W). The dosing will be initiated when at least two dose levels (DLs) of Part 1A have been evaluated.

Group Type: EXPERIMENTAL

Dazostinag

Intervention Type: DRUG

Dazostinag intravenous infusion.

Pembrolizumab

Intervention Type: DRUG

Pembrolizumab intravenous infusion.

Arm A: Japan Safety Lead-in Dazostinag + Pembrolizumab

Dazostinag 5.0 mg, infusion, IV, in Japanese participants with advanced or metastatic solid tumors on Days 1, 8, and 15 in each 21-day cycle in combination with pembrolizumab 200 mg administered Q3W, IV, on Day 1 in each 21-day cycle.

Additional dose levels of Dazostinag (such as 14.0 mg) in combination with pembrolizumab (200 mg, Q3W) may be explored in the Safety Lead-in.

Group Type: EXPERIMENTAL

Dazostinag

Intervention Type: DRUG

Dazostinag intravenous infusion.

Pembrolizumab

Intervention Type: DRUG

Pembrolizumab intravenous infusion.

Arm B: Japan Safety Lead-in Dazostinag Transitioned to Pembrolizumab

Dazostinag 5.0 mg, infusion, IV, as an SA once on Day 1 in Cycle 0 (cycle length=7 days) in Japanese participants with advanced or metastatic solid tumors based on confirmation of tolerability in Arm A. Following Cycle 0 (7 days), participants will be transitioned to the same dose level of dazostinag on Days 1, 8, and 15 of each 21-day cycle in combination with pembrolizumab administered Q3W, IV, on Day 1 in each 21-day cycle.

Additional dose levels of dazostinag (such as ≥ 7.0 mg) in combination with pembrolizumab (200 mg, Q3W) may be explored in the Safety Lead-in.

Group Type: EXPERIMENTAL

Dazostinag

Intervention Type: DRUG

Dazostinag intravenous infusion.

Pembrolizumab

Intervention Type: DRUG

Pembrolizumab intravenous infusion.

Part 2A (SCCHN CPS ≥ 1 Dose Expansion and Optimization Phase): Dazostinag + Pembrolizumab

Dazostinag 5.0 mg, infusion, IV, will be administered in participants with squamous cell carcinoma of head and neck (SCCHN) at the identified dose level from Part 1 on Days 1, 8, and 15 in a 21-day cycle along with pembrolizumab 200 mg infusion, IV, Q3W. Dose optimization may be performed in this phase.

Group Type: EXPERIMENTAL

Dazostinag

Intervention Type: DRUG

Dazostinag intravenous infusion.

Pembrolizumab

Intervention Type: DRUG

Pembrolizumab intravenous infusion.

Part 2B (SCCHN Dose Expansion Phase): Dazostinag + Pembrolizumab + Chemotherapy

Dazostinag 5.0 mg, infusion, IV, will be administered in participants with SCCHN at the identified dose level from Part 1 on Days 1, 8, and 15 in a 21-day cycle. Pembrolizumab infusion, IV will be administered at 200 mg Q3W. Platinum-based chemotherapy comprising the combination of carboplatin (target area under the curve of 5 milligrams per milli Liters per minute (mg/mL/minute) \[AUC 5\]) or cisplatin (100 milligrams per square meter \[mg/m\^2\] Day 1 of each treatment cycle), and 5-fluorouracil (\[5-FU\]; 1000 mg/m\^2 per day for 4 consecutive days) Q3W for up to 6 cycles.

Group Type: EXPERIMENTAL

Dazostinag

Intervention Type: DRUG

Dazostinag intravenous infusion.

Pembrolizumab

Intervention Type: DRUG

Pembrolizumab intravenous infusion.

Platinum

Intervention Type: DRUG

Carboplatin or Cisplatin intravenous infusion

5-fluorouracil

Intervention Type: DRUG

5-fluorouracil intravenous infusion

Part 3A (Expansion Phase in CRC): Dazostinag + Pembrolizumab in MSI-H/dMMR CRC

Dazostinag 5.0 mg, infusion, IV, will be administered in participants with microsatellite instability-high /mismatch repair deficient (MSI-H/dMMR) colorectal cancer (CRC) at the identified dose level from Part 1 on Days 1, 8, and 15 in a 21-day cycle along with pembrolizumab 200 mg infusion, IV, Q3W.

Group Type: EXPERIMENTAL

Dazostinag

Intervention Type: DRUG

Dazostinag intravenous infusion.

Pembrolizumab

Intervention Type: DRUG

Pembrolizumab intravenous infusion.

Part 3B (Expansion Phase in CRC): Dazostinag + Pembrolizumab in MSS/pMMR CRC

Dazostinag 5.0 mg, infusion, IV, will be administered in participants with microsatellite stable/mismatch repair proficient (MSS/pMMR) CRC at the identified dose level from Part 1 on Days 1, 8, and 15 in a 21-day cycle. along with pembrolizumab 200 mg infusion, IV, Q3W.

Group Type: EXPERIMENTAL

Dazostinag

Intervention Type: DRUG

Dazostinag intravenous infusion.

Pembrolizumab

Intervention Type: DRUG

Pembrolizumab intravenous infusion.

Interventions

Dazostinag

Dazostinag intravenous infusion.

Intervention Type: DRUG

Pembrolizumab

Pembrolizumab intravenous infusion.

Intervention Type: DRUG

Platinum

Carboplatin or Cisplatin intravenous infusion

Intervention Type: DRUG

5-fluorouracil

5-fluorouracil intravenous infusion

Intervention Type: DRUG

Other Intervention Names

TAK-676

Eligibility Criteria

Inclusion Criteria

1. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.

2. Dazostinag SA (dose escalation Part 1A):

o With histologically confirmed (cytological diagnosis is acceptable) advanced or metastatic solid tumors that have no standard therapeutic options or are intolerant to these therapies.

3. Dazostinag in combination with pembrolizumab (dose escalation Parts 1B and Japan safety lead-in):

• With histologically confirmed (cytological diagnosis is acceptable) advanced or metastatic solid tumors that have no standard therapeutic options or are intolerant to them, including:
• Tumors that have relapsed or are refractory to anti-programmed cell death ligand protein 1 (anti PD-(L)-1) therapy.
• Tumors that are naive to anti-PD-(L)-1 therapy.

4. For expansion phase only:

• SCCHN (Part 2):
• Participants with histologically confirmed (cytological diagnosis is acceptable) metastatic or recurrent, unresectable SCCHN that is considered incurable by local therapies. Participants should not have had prior systemic therapy administered in the recurrent or metastatic setting. Systemic therapy which was completed more than 6 months before signing consent if given as part of multimodal treatment of locally advanced disease is allowed.
• Anatomic subsites to be included are oral cavity, oropharynx, hypopharynx, larynx, nasal cavity, and paranasal sinuses (maxillary, ethmoid, sphenoid, and frontal). The exception to this is nasopharyngeal cancer and salivary gland tumors, which will not be included.
• Participants with oropharyngeal cancer or tumors arising in the paranasal sinuses (maxillary, ethmoid, sphenoid, and frontal) must agree to provide archival tissue for human papilloma virus (HPV) testing or if known, HPV testing results (using CINtec® p16 Histology assay is preferred but not required) and a 70% cutoff point must be provided. Alternatively, archival tissue or a fresh excisional or core needle biopsy (≥ 2 cores) is required for the determination of HPV status. If HPV status was previously tested using this method (CINtec® p16 Histology assay is preferred but not required), no additional testing is required. Archival tissue can be obtained up to 90 days prior to screening. Samples that are older than 90 days at screening may be used after consultation with the sponsor.
• For Part 2A, tumors must have a PD-L1 CPS ≥ 1. Participants must agree to provide fresh tumor biopsy for analysis from a core or excisional biopsy (fine needle aspirate is not sufficient) at screening for PD-L1 CPS assessment by a central laboratory. This specimen may be the diagnostic sample for participants with a new diagnosis of metastatic SCCHN. Participants for whom newly obtained samples cannot be obtained (eg, inaccessible or participant safety concern) may submit an archived specimen only upon agreement from the Sponsor. Archival tissue can be obtained up to 90 days prior to screening provided there was no other treatment from the time of biopsy until the start of study treatment. For Part 2B, any CPS is eligible but fresh or archival tissue is required for confirmation of CPS status. Collection of the tissue samples for PD-L1 assessments for Part 2B can be discontinued by the sponsor if sufficient data has been collected or dazostinag activity does not justify further collection.
• For Part 2B, participants must be eligible to receive treatment with either cisplatin or carboplatin in combination with 5-fluorouracil (5-FU) per the treating physician.

5. CRC (Part 3):

• Third-line or later MSI-H/dMMR CRC (Part 3A): Participants with histologically confirmed (cytological diagnosis is acceptable) recurrent locally advanced or metastatic MSI-H/dMMR CRC whose disease has progressed on or following therapy with 1) an anti-PD-1 or PD-L1 antibody (i.e., pembrolizumab) and 2) at least one line of combination chemotherapy including a fluoropyrimidine and irinotecan OR oxaliplatin with or without an anti-epidermal growth factor receptor (EGFR) or anti-vascular endothelial growth factor (VEGFR) monoclonal antibody (i.e., cetuximab or bevacizumab). MSI-H/dMMR CRC participants must have received at least 6 weeks of prior treatment with an anti-PD-(L)-1 antibody. Only one line of anti-PD-(L)-1 is permitted.
• Third-line MSS/pMMR CRC (Part 3B): Participants with histologically confirmed (cytological diagnosis is acceptable) recurrent locally advanced or metastatic MSS/pMMR CRC whose disease has progressed on or following therapy with 2 different lines of combination chemotherapy, including therapy with a fluoropyrimidine and irinotecan AND therapy with a fluoropyrimidine and oxaliplatin. Both lines of therapy may be given with or without an anti-EGFR or anti-VEGFR monoclonal antibody (i.e., cetuximab or bevacizumab).

Participants with MSS/pMMR CRC must have progressed on or after combination chemotherapy regimens containing BOTH irinotecan AND oxaliplatin.

• Participants with MSI-H/dMMR or MSS/pMMR CRC must have documented MSI/MMR status assessed by a Clinical Laboratory Improvements Amendment-certified (United States [US] sites or an accredited (outside of the US) local laboratory using immunohistochemistry (IHC) and/or polymerase chain reaction (PCR) or next generation sequencing (NGS) assay.
• Adequate tumor tissue available for central laboratory confirmation of MSI/MMR status. Note: confirmation of central test positivity is not required before treatment.
• Participants with MSI-H/dMMR or MSS/pMMR CRC must have been treated with 2 prior lines of therapy in the recurrent locally advanced or metastatic setting.

6. Adequate bone marrow, renal, hepatic and cardiac functions.

7. Left ventricular ejection fraction (LVEF) > 50%, as measured by echocardiogram or multiple-gated acquisition (MUGA) scan within 4 weeks before receiving the first dose of study drug.

8. Clinically significant toxic effects of previous therapy have recovered to Grade 1 (per NCI CTCAE Version 5.0) or baseline, except for alopecia, Grade 2 peripheral neuropathy, and/or autoimmune endocrinopathies with stable endocrine replacement therapy.

9. In dose escalation Part 1, (not applicable for the Japan safety lead-in) once peripheral evidence of dazostinag pharmacodynamic stimulation of the innate and/or adaptive immune system is observed in the blood and/or an imaging response/partial response (CR/PR) is observed in at least 1 participant, subsequent participants must:

• Have at least 1 lesion amenable for biopsy.
• Agree to have 2 tumor biopsies: 1 during the screening period and 1 while on dazostinag treatment.

10. Must have at least 1 RECIST version 1.1-evaluable (measurable) lesion. For the dose escalation phase (Part 1) only, nonmeasurable only disease is acceptable.

11. Pharmacokinetic (PK)/pharmacodynamic blood must be drawn on a peripherally-inserted catheter. Dazostinag is preferentially administered through a central line, but peripheral infusion is acceptable. If a peripheral line is used for dazostinag and/or pembrolizumab infusion, it must be separate than the one used for PK/pharmacodynamic collection.

Exclusion Criteria

1. Corrected QT interval by Fredericia (QTcF) greater than (>) 450 milliseconds (men) or > 475 milliseconds (women) on a 12-lead electrocardiogram (ECG) during the screening period.

2. Grade greater than or equal to (≥) 2 hypotension (that is, hypotension for which nonurgent intervention is required) at screening or during Cycle 0 Day 1 (C0D1) [for Japan safety lead-in only] and Cycle 1 Day 1 (C1D1) predose assessment.

3. Oxygen saturation less than (<) 92 percent (%) on room air at screening or during C0D1 (for Japan safety lead-in only) and C1D1 predose assessment.

4. Treated with other STING agonists/antagonist and toll-like receptors agonists within the past 6 months.

5. Current history of pneumonitis, interstitial lung disease, severe chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, other restrictive lung diseases, acute pulmonary embolism, or Grade ≥ 2 pleural effusion or ascites not controlled by tap or requiring indwelling catheters.

6. History of brain and leptomeningeal metastasis unless:

• Brain metastases are clinically and radiologically stable or improved (that is, ≥ 4 weeks) following surgery, whole-brain radiation, or stereotactic radiosurgery, AND
• Off corticosteroids.

7. Ongoing Grade ≥ 2 infection or participants with Grade ≥ 2 fever of malignant origin.

8. Chronic, active hepatitis (example: participants with known hepatitis B surface antigen seropositive and/or detectable hepatitis C virus [HCV]- ribonucleic acid [RNA]).

9. For participants in the dose escalation SA Part 1A only: refusal of standard therapeutic options.

10. For participants receiving pembrolizumab only: contraindication and/or intolerance to the administration of pembrolizumab.

11. For participants receiving chemotherapy in Part 2B: contraindication and/or intolerance to the administration of both platinum agents (cisplatin and carboplatin) and/or 5-FU.

12. Participant has had any other prior or concurrent malignancy within 2 years prior to enrollment with the following exceptions: adequately treated localized basal cell or squamous cell carcinoma, or curatively treated in situ carcinoma of the cervix or breast. Other exceptions may be considered upon sponsor consultation.

13. Concurrent chemotherapy (except for Part 2B), immunotherapy (except for pembrolizumab in Part 1B, Part 2, and Part 3), biologic, or hormonal therapy (except for adjuvant endocrine therapy for a history of breast cancer). Concurrent use of hormones for noncancer-related conditions is acceptable (except for corticosteroid hormones) unless allowed per exclusion criterion 16.

14. Radiation therapy within 14 days (42 days for radiation to the lungs) and/or systemic treatment with radionuclides within 42 days before C1D1 of study drug(s). Participants with clinically relevant ongoing pulmonary complications from prior radiation therapy are not eligible.

15. Use of systemic corticosteroids or other immunosuppressive therapy, concurrently or within 7 days of C1D1 of study drug(s), with the following exceptions:

• Topical, intranasal, inhaled, ocular, intra-articular, and/or other non-systemic corticosteroids.
• Premedications required for computed tomography (CT) or magnetic resonance imaging (MRI) scans.
• Physiological doses of replacement steroid therapy (example: for adrenal insufficiency).
• For participants enrolled in Part 2B, chemotherapy premedication with steroids can be administered according to local standards of care practice.

16. Use of medications that are known clinical organic anion-transporting polypeptide B1 (OATP1B1) and/or OATP1B3 inhibitors, concurrently or within 14 days of C1D1 of study drug(s).

17. Receipt of live attenuated vaccine (eg, tuberculosis Bacillus Calmette-Guerin vaccine, oral polio vaccine, measles, rotavirus, yellow fever) within 28 days of C1D1 of study drug(s).

18. Recipients of allogeneic or autologous stem cell transplantation or organ transplantation.

For Part 2 SCCHN only:

19. Has progressive disease within 6 months of completion of curatively intended systemic treatment for locoregionally advanced SCCHN.

20. Has a life expectancy of less than 3 months and/or has rapidly progressive disease (eg, tumor bleeding, uncontrolled tumor pain) in the opinion of the treating investigator.

21. Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2 or anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) agent.

22. Participants with known dihydropyrimidine dehydrogenase (DPD) deficiency or thymidine phosphorylase gene (TYMP) mutations (Part 2B only).

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Takeda

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Study Director

Role: STUDY_DIRECTOR

Takeda

Locations

University of California San Diego Moores Cancer Center

La Jolla, California, United States

Norris Comprehensive Cancer Center

Los Angeles, California, United States

UCI Health - Chao Family Comprehensive Cancer Center

Orange, California, United States

University of California Los Angeles - Jonsson Comprehensive Cancer Center

Santa Monica, California, United States

SCRI - HealthOne Denver

Denver, Colorado, United States

Yale Cancer Center

New Haven, Connecticut, United States

Memorial Cancer Institute at Memorial Hospital West - Cancer Institute/Radiology Oncology

Gainesville, Florida, United States

Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Chicago, Illinois, United States

University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center

Baltimore, Maryland, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

Dana-Farber Cancer Institute

Boston, Massachusetts, United States

Barbara Ann Karmanos Cancer Institute - Lawrence and Idell Weisberg Cancer Treatment Center

Detroit, Michigan, United States

Siteman Cancer Center - St. Peters

City of Saint Peters, Missouri, United States

Siteman Cancer Center - West County

Creve Coeur, Missouri, United States

Siteman Cancer Center - North County

Florissant, Missouri, United States

Washington University School of Medicine Siteman Cancer Center

St Louis, Missouri, United States

Siteman Cancer Center - South County

St Louis, Missouri, United States

University of Cincinnati Health Barrett Cancer Center

Cincinnati, Ohio, United States

University of Cincinnati Health Barrett Cancer Center

Cincinnati, Ohio, United States

West Chester Hospital

West Chester, Ohio, United States

Providence Portland Medical Center

Portland, Oregon, United States

Fox Chase Cancer Center

Philadelphia, Pennsylvania, United States

University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center

Pittsburgh, Pennsylvania, United States

Sarah Cannon Research Institute (SCRI)

Nashville, Tennessee, United States

Mary Crowley Cancer Research

Dallas, Texas, United States

Virginia Cancer Specialists, P.C. - Fairfax

Fairfax, Virginia, United States

Klinikum Wels-Grieskirchen

Wels, Upper Austria, Austria

Princess Margaret Cancer Centre

Toronto, Ontario, Canada

Jewish General Hospital

Montreal, Quebec, Canada

McGill University Health Centre

Montreal, Quebec, Canada

Beijing Cancer Hospital

Beijing, Beijing Sheng, China

Sixth Affiliated Hospital of Sun Yat-Sen University/Guangdong Gastrointestinal Hospital

Guangzhou, Guangzhou Sheng, China

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China

Shanghai East Hospital

Shanghai, Shanghai Municipality, China

West China Hospital

Chengdu, Sichuan, China

West China School of Medicine - West China Hospital of Sichuan University

Chengdu, Sichuan, China

Zhejiang Cancer Hospital

Hangzhou, Zhejiang, China

Centre Hospitalier Regional et Universitaire de Besancon - Hopital Jean-Minjoz

Besançon, , France

Hopital Saint-Andre

Bordeaux, , France

Centre Georges Francois Leclerc

Dijon, , France

Centre de Lutte contre le Cancer - Centre Oscar Lambret

Lille, , France

Centre Leon Berard

Lyon, , France

Hopital de la Timone

Marseille, , France

Hopital Saint-Antoine

Paris, , France

Institut de Cancerologie de lOuest - Saint-Herblain - Site Rene Gauducheau

Saint-Herblain, , France

Gustave Roussy

Villejuif, , France

Hopital Foch

Suresnes, Île-de-France Region, France

Soroka Medical Center

Beersheba, , Israel

Hadassah University Hospital Ein Kerem

Jerusalem, , Israel

Tel Aviv Sourasky Medical Center

Tel Aviv, , Israel

The Chaim Sheba Medical Center

Tel Litwinsky, , Israel

National Cancer Center Hospital

Chuo-Ku, Tokyo, Japan

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy

Warsaw, Masovian Voivodeship, Poland

PanOncology Trials: Universidad de Puerto Rico - Centro Comprensivo de Cancer

San Juan, , Puerto Rico

Kantonsspital Sankt Gallen

Sankt Gallen, Canton of St. Gallen, Switzerland

Inselspital Universitatsspital Bern

Bern, , Switzerland

Hopitaux Universitaires de Geneve

Geneva, , Switzerland

Centre Hospitalier Universitaire Vaudois Lausanne

Lausanne, , Switzerland

Queen's University Belfast

Belfast, Northern Ireland, United Kingdom

Leeds Teaching Hospitals NHS Trust

Leeds, , United Kingdom

University College London Hospitals NHS Foundation Trust

London, , United Kingdom

Oxford University Hospitals NHS Foundation Trust

Oxford, , United Kingdom

Countries

United States; Austria; Canada; China; France; Israel; Japan; Poland; Puerto Rico; Switzerland; United Kingdom

References

Carideo Cunniff E, Sato Y, Mai D, Appleman VA, Iwasaki S, Kolev V, Matsuda A, Shi J, Mochizuki M, Yoshikawa M, Huang J, Shen L, Haridas S, Shinde V, Gemski C, Roberts ER, Ghasemi O, Bazzazi H, Menon S, Traore T, Shi P, Thelen TD, Conlon J, Abu-Yousif AO, Arendt C, Shaw MH, Okaniwa M. TAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies. Cancer Res Commun. 2022 Jun 23;2(6):489-502. doi: 10.1158/2767-9764.CRC-21-0161. eCollection 2022 Jun.

Reference Type: DERIVED

PMID: 36923556 (View on PubMed)

Related Links

https://clinicaltrials.takeda.com/study-detail/5f6b603d4db2bf003ab4a3a7

To obtain more information on the study, click here/on this link

Other Identifiers

U1111-1241-4427

Identifier Type: REGISTRY

Identifier Source: secondary_id

2023-505627-30-00

Identifier Type: CTIS

Identifier Source: secondary_id

jRCT2031230532

Identifier Type: REGISTRY

Identifier Source: secondary_id

TAK-676-1002

Identifier Type: -

Identifier Source: org_study_id